In 2022, Dongsheng Pharmaceutical introduced a large state-owned listed company, Jinling Pharmaceutical Co., Ltd., as the controlling shareholder, and Nanjing Aide Kaiteng Biopharmaceutical Co., Ltd. as the participating shareholder. Dongsheng Pharmaceutical has fully launched the overall planning and construction of new and old factory areas, as well as the comprehensive management project of safety and environmental protection facilities. In the next two to three years, Dongsheng Pharmaceutical will accelerate the high-quality development of Dongsheng Pharmaceutical through resource integration, relying on growth and strength.

Jinling Pharmaceutical is a state-owned listed company that focuses on the research and development, production, sales, medical treatment, health care, elderly care, and nursing of Western medicine raw materials, preparations, and medical devices; We have a variety of production lines for various types of formulations.
Adekton is a new drug research and development company that integrates pharmaceutical research and development outsourcing, and holds drug marketing licenses.

Dongsheng Pharmaceutical has many years of experience in the production and approval of raw materials and high-end pharmaceutical intermediates. Our existing one-stop service enables us to achieve higher professionalism, stronger stability, improved efficiency, and cost savings.